Eosinophilic EsophagitisPhase 2VOYAGENCT04682639
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
A Phase 2 study testing Etrasimod in people with Eosinophilic Esophagitis, run by Pfizer at 256 sites in 8 countries.
Trial summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Eosinophilic Esophagitis
- What is being tested?
- Etrasimod
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 108 participants
- Where
- 256 sitesin 8 countries
- Study dates
- 15 Dec 2020to 30 Jun 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have an eosinophilic esophagitis (EoE) diagnosis prior to screening and histologically active disease with an esophageal peak eosinophil count (PEC) of ≥ 15 eosinophils per high powered field (eos/hpf)
- Have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the Screening period
- Completion of the Week 24 study visit [including esophagogastroduodenoscopy (EGD)]
- Compliance with study procedures during the Double-Blind Treatment Period as assessed by the Investigator
- No notable safety concerns during the Double-Blind Treatment Period, as determined by the Investigator
- Willing to comply with all study visits and procedures for the Extension Treatment Period
Who cannot join
- History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study
- Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD
- Use of corticosteroids for the treatment of EoE within 8 weeks prior to Screening EGD
- Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:
- Elemental diet
- EoE food trigger elimination diet
Show all 11Show fewer
- Proton pump inhibitor (PPI) therapy
- Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation
- Used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to Baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time)
- Use of any investigational agent or device within 12 weeks prior to Baseline
- Females who are pregnant
Trial locations and contacts
256 sites in 8 countries.
256 sites in 8 countries
United States221 sites
Digestive Healthcare of Georgia
Atlanta, Georgia, 30309
Peachtree Allergy and Asthma Clinica - Pulmonary Function Test
Atlanta, Georgia, 30309
Piedmont Hospital- DLCO
Atlanta, Georgia, 30309
Ross Eyecare - Opthalmoscopy and OCT
Atlanta, Georgia, 30324
Clinical Research Center of Alabama, LLC
Birmingham, Alabama, 35209
GastroHealth - St. Vincent's East
Birmingham, Alabama, 35235
RecioMed Clinical Research Network, Inc
Boynton Beach, Florida, 33472
Steelgate
Bradenton, Florida, 34203
Del Negro & Senft Eye Associates
Brick, New Jersey, 08723
Allied Health Clinical Research Organization, LLC (IP Address)
Brick, New Jersey, 08724
Seashore Surgical Institute
Brick, New Jersey, 08724
Shore Pulmonary, PA
Brick, New Jersey, 08724
West Shore Endoscopy Center
Camp Hill, Pennsylvania, 17011
lnvestigational Drug Services, University of North Carolina Hospitals (IP storage address)
Chapel Hill, North Carolina, 27514
UNC Clinical Research Eastowne
Chapel Hill, North Carolina, 27514
UNC Hospitals Pulmonary Function Lab (PFT and DLCO procedures only)
Chapel Hill, North Carolina, 27514
University of North Carolina - Memorial Hospital
Chapel Hill, North Carolina, 27514
UNC Endoscopy Center at Meadowmont
Chapel Hill, North Carolina, 27517
UNC Hospitals Pulmonary Specialty Clinic (PFT and DLCO procedures only)
Chapel Hill, North Carolina, 27517
UNC Kittner Eye Center (OCT procedure only)
Chapel Hill, North Carolina, 27517
Clinical and Translational Research Center Outpatient Unit
Chapel Hill, North Carolina, 27599-7064
Geauga Sleep Center (PFT Only)
Chardon, Ohio, 44024
Chesapeake Pulmonary and Critical Care Medicine (PFT Only)
Chesapeake, Virginia, 23320
Gastroenterology Associates of Tidewater - Endoscopy Center
Chesapeake, Virginia, 23320
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611
Leon A. Reid, III, M.D. (OCT)
Cincinnati, Ohio, 45209
Cincinnati Eye Institute (ophthalmic and OCT exams)
Cincinnati, Ohio, 45219
Consultants for Clinical Research
Cincinnati, Ohio, 45219
Gastro Health Research
Cincinnati, Ohio, 45219
Ohio GI and Liver Institute
Cincinnati, Ohio, 45219
Tristate Endoscopy Center (Endoscopy)
Cincinnati, Ohio, 45219
UC Health Hoxworth (ophthalmic and OCT only)
Cincinnati, Ohio, 45219
UC Health Physicians Office Clifton (where subjects seen)
Cincinnati, Ohio, 45219
UC Health Pulmonary (PFT Location)
Cincinnati, Ohio, 45219
University of Cincinnati Medical Center Diagnostic Center (Endoscopy location)
Cincinnati, Ohio, 45219
UC Health Pulmonary (Pulmonary Function Testing)
Cincinnati, Ohio, 45229
Leon A. Reid, III, M.D. (OCT)
Cincinnati, Ohio, 45236
New Horizons Clinical Research (PFT)
Cincinnati, Ohio, 45242
University Endoscopy Center (Endoscopy location)
Cincinnati, Ohio, 45242
UC Health/Division of Digestive Diseases (where subjects seen)
Cincinnati, Ohio, 45267
Bay Area Chest Physicians, P.A., - Pulmonary Function Test
Clearwater, Florida, 33756
West Coast Endoscopy Center
Clearwater, Florida, 33756
West Coast Endoscopy
Clearwater, Florida, 33756
MACULA CENTER Dana M. Deupree, M.D., F.A.C.S (OCT)
Clearwater, Florida, 33761
Northwood Vision Optical Coherence Tomography (OCT)
Clearwater, Florida, 33761
Safety Harbor Surgery Center
Clearwater, Florida, 33761
Gastro Florida (Regulatory & Administrative Duties)
Clearwater, Florida, 33762
Erdey Searcy Eye Group
Columbus, Ohio, 43213
Beraja Medical Institute (OCT)
Coral Gables, Florida, 33134
Bayfront Health Seven Rivers (Liver Biopsy Location)
Crystal River, Florida, 34428
Citrus Surgery and Endoscopy Center (EGD Location)
Crystal River, Florida, 34429
Digestive Health Center (Endoscopy)
Dallas, Texas, 75231
Georgia Eye Partners
Decatur, Georgia, 30030
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia, 30033
Atlanta Endoscopy Center LTD
Decatur, Georgia, 30033
Pulmonary & Sleep Specialist
Decatur, Georgia, 30033
Digestive Health Specialists
Dothan, Alabama, 36301
Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only)
Dothan, Alabama, 36301
Dothan Surgery Center (Colonoscopy Location)
Dothan, Alabama, 36301
Pulmonary Associates (PFT Procedure Only, Second Location )
Dothan, Alabama, 36301
Flowers Hospital (PFT Procedure Only)
Dothan, Alabama, 36305
Ohio Gastroenterology Group
Dublin, Ohio, 43016
Duke Medical Plaza North Duke Street
Durham, North Carolina, 27704
Duke Eye Center
Durham, North Carolina, 27705
Duke University Medical Center
Durham, North Carolina, 27710
Investigational Drug Services (Pharmacy)
Durham, North Carolina, 27710
Coastal Research Institute
Fayetteville, North Carolina, 28304
Cumberland Research Associates, LLC
Fayetteville, North Carolina, 28304
Harman Eye Center (OCT only)
Forest, Virginia, 24551
Isight Vision Care
Fountain Valley, California, 92708
Mile Square Surgery Center
Fountain Valley, California, 92708
Pulmonary & Sleep Consultants
Fountain Valley, California, 92708
Allied Health Clinical Research Organization, LLC
Freehold, New Jersey, 07728
Paragon Rx Clinical, Inc.
Garden Grove, California, 92840
Glen Endoscopy Center (Endoscopy Facility)
Glenview, Illinois, 60026
GI Alliance (PFT)
Gurnee, Illinois, 60031
Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
Gurnee, Illinois, 60031
Medical Eye Services LTD (Ophthalmoscopy with OCT)
Gurnee, Illinois, 60031
Medical Arts Allergy,PC (PFT Only)
Harrisburg, Pennsylvania, 17109
Farrel Opthalmology(OCT only)
Harrisburg, Pennsylvania, 17110
Susquehanna Research Group, LLC
Harrisburg, Pennsylvania, 17110
Harrisburg Eye Associates (OCT only)
Harrisburg, Pennsylvania, 17111
Advanced Eye Center
Hialeah, Florida, 33012
UNC Gastroenterology at Hillsborough
Hillsborough, North Carolina, 27278
Precision for Medicine
Houston, Texas, 77054
Avant Research Associates, LLC
Huntsville, Alabama, 35802
Crestwood Medical Center
Huntsville, Alabama, 35802
Baily Cove Eye Care
Huntsville, Alabama, 35803
Grand Teton Research Group, PLLC
Idaho Falls, Idaho, 83404
Grand Teton Surgical Center
Idaho Falls, Idaho, 83404
Idaho Falls Pulmonary/ Sleep and Critical Care Specialists (PFT procedure only)
Idaho Falls, Idaho, 83404
Premier Eye Care of Eastern Idaho (OCT procedure only)
Idaho Falls, Idaho, 83404
Nature Coast Clinical Research
Inverness, Florida, 34452
West Coast Eye Institute (OCT Procedure Only)
Inverness, Florida, 34452
Suncoast Endoscopy Center (EGD Location)
Inverness, Florida, 34453
Clark Memorial Health (PFTs)
Jeffersonville, Indiana, 47130
One Anesthesia, AACC Division
Jeffersonville, Indiana, 47130
Franklin Woods Community Hospital (PFT Only)
Johnson City, Tennessee, 37604
Pulmonary Associates of ET/Jeff Farrow, MD - PFT only
Johnson City, Tennessee, 37604
Jupiter Outpatient Surgery Center
Jupiter, Florida, 33458
The Regional Eye Center - OCT only
Kingsport, Tennessee, 37660
Tri-Cities Gastroenterology
Kingsport, Tennessee, 37663
Acadiana Endoscopy Center, Inc
Lafayette, Louisiana, 70503
Acadiana Gastroenterology Associates
Lafayette, Louisiana, 70503
Combined Gastro Research, LLC
Lafayette, Louisiana, 70503
Gastroenterology Clinic of Acadiana (IP address)
Lafayette, Louisiana, 70503
Lafayette General Endoscopy Center
Lafayette, Louisiana, 70503
Lafayette Family Eye Care
Lafayette, Louisiana, 70508
North Shore Endoscopy Center (Endoscopy)
Lake Bluff, Illinois, 60044
Inland Pulmonary Specialists [PFT Only]
Lake Elsinore, California, 92532
Central Florida Sleep Diagnostic & Treatment Center
Lakeland, Florida, 33812
Auzmer Research
Lakeland, Florida, 33813
Advanced Endoscopy and Pain Center - EGD & Biopsy Collection
Lancaster, California, 93534
Advanced Endoscopy and Pain Center
Lancaster, California, 93534
Antelope Valley Eye Care - OCT
Lancaster, California, 93534
Antelope Valley Eye Care
Lancaster, California, 93534
Antelope Valley Lung and Sleep Institute
Lancaster, California, 93534
Apollo Surgery Center
Lancaster, California, 93534
AV Pediatrics, Allergy and Family Medicine - PFT, Physical Exams, Lab Reviews, ECG Reviews
Lancaster, California, 93534
Gastro Care Institute
Lancaster, California, 93534
Jatinder S. Pruthi, MD FACG CPI - Physical Exams, Lab Reviews, ECG Reviews
Lancaster, California, 93534
Om Research LLC
Lancaster, California, 93534
West Coast Eye Institute (OCT Procedure Only)
Lecanto, Florida, 34453
Penn State Health Medical Group - Lemoyne (PFT only)
Lemoyne, Pennsylvania, 17043
Quest
Lenexa, Kansas, 66219
Libertyville Imaging Center (Diagnostic Imaging)
Libertyville, Illinois, 60048
Celerion, Inc.
Lincoln, Nebraska, 68502
Little Rock Eye Clinic
Little Rock, Arkansas, 72205
Four Seasons Allergy and Asthma
Little Rock, Arkansas, 72211
Applied Research Center of Arkansas
Little Rock, Arkansas, 72212
Premier Gastroenterology Endoscopy Center
Little Rock, Arkansas, 72212
Premier Gastroenterology
Little Rock, Arkansas, 72212
Clinical Trials Unit
Los Angeles, California, 90033
Keck Hospital of USC
Los Angeles, California, 90033
USC IDS Pharmacy
Los Angeles, California, 90033
Advanced Vision Care (OCT)
Los Angeles, California, 90067
Lynchburg Pulmonary Associates, Inc. (PFT only)
Lynchburg, Virginia, 24501
Blue Ridge Medical Research
Lynchburg, Virginia, 24502
Madison Surgery Center
Madison, Alabama, 35758
Great Lakes Medical Research, LLC
Mentor, Ohio, 44060
The Endoscopy Center of Lake County
Mentor, Ohio, 44060
The Endoscopy Center (Endoscopy Procedure)
Miami, Florida, 33134
Research Associates of South Florida
Miami, Florida, 33137
Research Associates of South Florida
Miami, Florida, 33156
Juan Barrio, MD (PFT when needed)
Miami, Florida, 33173
M Health Fairview Clinics and Surgery Center
Minneapolis, Minnesota, 55455
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota, 55455
University of Minnesota Health Clinical research unit
Minneapolis, Minnesota, 55455
University of Minnesota Health Opthalmology Clinic
Minneapolis, Minnesota, 55455
United Surgery Center Murrieta [Endoscopy Only]
Murrieta, California, 92562
United Medical Doctors
Murrieta, California, 92563
Vanderbilt GI Endoscopy Lab at One Hundred Oaks
Nashville, Tennessee, 37204
Vanderbilt University Medical Center - GI Research Office
Nashville, Tennessee, 37212-1610
Vanderbilt University Medical Center GI Endoscopy Lab
Nashville, Tennessee, 37232-5543
Vanderbilt Eye Institute
Nashville, Tennessee, 37232
Vanderbilt Pulmonary Medicine
Nashville, Tennessee, 37232
Vanderbilt University Medical Center - Digestive Disease Center
Nashville, Tennessee, 37232
Vanderbilt University Medical Center - Heart Station
Nashville, Tennessee, 37232
Del Negro & Senft Eye associates
Neptune City, New Jersey, 07753
Baptist Health Floyd (PFTs)
New Albany, Indiana, 47150
Gastroenterology Health Partners, PLLC, (IP)
New Albany, Indiana, 47150
John Kenyon Eye Center (OCT)
New Albany, Indiana, 47150
One Anesthesia, PLLC
New Albany, Indiana, 47150
Physicians Medical Center (Endoscopies)
New Albany, Indiana, 47150
CHRJSTUS Santa Rosa Physicians Ambulatory Surgery Center-new Braunfels(Endoscopy)
New Braunfels, Texas, 78130
Tyrus Schroeder (PFT)
New Braunfels, Texas, 78130
Wagner Macula and Retina Center (OCT only)
Norfolk, Virginia, 23322
Wagner Macula and Retina Center (OCT only)
Norfolk, Virginia, 23502
Norman Endoscopy Center
Norman, Oklahoma, 73071
Digestive Disease Specialists, Inc. Endoscopy Lab
Oklahoma City, Oklahoma, 73112
Digestive Disease Specialists, Inc.
Oklahoma City, Oklahoma, 73112
Pulmonary Physicians of Oklahoma
Oklahoma City, Oklahoma, 73112
Retinal Center of Oklahoma
Oklahoma City, Oklahoma, 73112
Central Sooner Research
Oklahoma City, Oklahoma, 73118
Johnston Eye
Oklahoma City, Oklahoma, 73120
Vitreo Retinal Consultants (OCT only)
Painesville, Ohio, 44077
Arizona Retina Institute/ Phoenix Retina Associates(OCT)
Peoria, Arizona, 85381
SimonMed Imaging (Imaging)
Peoria, Arizona, 85381
Investigational Drug Services
Philadelphia, Pennsylvania, 19104
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
The Eye Place Jenny Fan, OD (OCT Only)
Plano, Texas, 75074
Brier Creek Medical Pavilion
Raleigh, North Carolina, 27617
Rapid City Medical Center, LLP
Rapid City, South Dakota, 57701
Del Negro & Senft eye Associates
Red Bank, New Jersey, 07701
Pulmonary Medicine Consultants (PFT with DCLO only)
Richardson, Texas, 75082
Florida Eye Specialists and Cataract Institute
Riverview, Florida, 33579
Mayo Clinic
Rochester, Minnesota, 55905
University of Utah Gastroenterology Division Research
Salt Lake City, Utah, 84108
Huntsman Cancer Hospital
Salt Lake City, Utah, 84112
University of Utah Hospital
Salt Lake City, Utah, 84132
University Of Utah School Of Medicine
Salt Lake City, Utah, 84132
Advanced Imaging
San Marcos, Texas, 78666
Central Texas Eye Center (OCT)
San Marcos, Texas, 78666
CHRJSTUS Santa Rosa Physicians Ambulatory Surgery Center - San Marcos (Endoscopy)
San Marcos, Texas, 78666
Dr. Dennis Bassetti, MD
Sebring, Florida, 33870
Highlands Eye Institute, P.A.
Sebring, Florida, 33870
The Surgery and Endoscopy Center
Sebring, Florida, 33870
Arizona Digestive Health - Sun City
Sun City, Arizona, 85351
Sun City Endoscopy Center (Endoscopy)
Sun City, Arizona, 85351
Ambulatory Surgery Center
Tampa, Florida, 33613
Pulmonology & Sleep Disorders
Tampa, Florida, 33613
California Eye Professionals [OCT Only]
Temecula, California, 92591
United Surgery Center Temecula [Endoscopy Only]
Temecula, California, 92592
Cotton O'Neil Clinic (OCT Procedure Only)
Topeka, Kansas, 66606
Cotton O'Neil Clinic (PFT Procedure Only)
Topeka, Kansas, 66606
Cotton O'Neil Clinical Research Center, Digestive Health
Topeka, Kansas, 66606
Alabama Eye MD
Vestavia Hills, Alabama, 35216
Sleep Specialists of Tidewater - Virginia Beach (PFT Only)
Virginia Beach, Virginia, 23464
Bay Area Houston Endoscopy Center (Endoscopy)
Webster, Texas, 77598
Coastal Eye Associates (OCT)
Webster, Texas, 77598
GI Alliance (Patients Seen)
Webster, Texas, 77598
Houston Lung and Sleep Clinic, PA (PFT)
Webster, Texas, 77598
Tower Health Reading Hospital
West Reading, Pennsylvania, 19611
Lake Pulmonary Associates (PFT only)
Willoughby, Ohio, 44094
Retina Specialists of Ohio(OCT only)
Willoughby Hills, Ohio, 44094
Day Surgery Center
Winter Haven, Florida, 33884
Berks Center for Digestive Health
Wyomissing, Pennsylvania, 19610
Berks Schuylkill Respiratory Specialists "PFT Procedure Only"
Wyomissing, Pennsylvania, 19610
Eye Consultants of Pennsylvania, PC "OCT Procedure Only"
Wyomissing, Pennsylvania, 19610
Regional Gastroenterology Associates of Lancaster, Ltd.
Wyomissing, Pennsylvania, 19610
Australia23 sites
MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons (OCT Facility)
Bellfield, 3081
Sunshine University Private Hospital
Birtinya, Queensland, 4575
Queensland Respiratory Services ,Pulse Oceanside Medical{PFT Facility )
Birtinya, 4575
Eastern Clinical Research Unit
Box Hill, Victoria, 3128
Eastern Health
Box Hill, Victoria, 3128
Box Hill Eye Surgeons (OCT Facility)
Box Hill North, Victoria, 3129
Mater Misericordiae Ltd
Brisbane South, Queensland, 4101
Buderim Eye Centre (OCT Facility)
Buderim, Queensland, 4558
Retina Specialists Victoria (OCT Facility)
Camberwell, Victoria, 3124
Elizabeth Specialist Suites (PFT Facility)
Elizabeth Vale, South Australia, 5112
Lyell McEwin Hospital.
Elizabeth Vale, South Australia, 5112
Lyell McEwin Hospital
Elizabeth Vale, South Australia, 5112
The Northern Hospital
Epping, Victoria, 3076
Footscray Hospital
Footscray, Victoria, 3011
Dr Shiran DeSilva Respiratory Clinic
Mackay, Queensland, 4740
Mackay Discount Drug Store
Mackay, Queensland, 4740
Mater Misericordiae Hospital
Mackay, Queensland, 4740
Queensland X-Ray
Mackay, Queensland, 4740
Vision Eye Institute Mackay
Mackay, Queensland, 4740
Coastal Digestive Health
Maroochydore, Queensland, 4558
Vision Eye Institute
Melbourne, Victoria, 3011
Modbury Hospital (OCT Facility)
Modbury, South Australia, 5092
Coral Sea Clinical Research Institute
North Mackay, Queensland, 4740
Belgium3 sites
AZ St Lucas Brugge
Bruges, 8310
AZ Delta
Roeselare, 8800
Centre Hospitalier Wallonie Picarde (CHWAPI)
Tournai, 7500
Spain3 sites
Hospital General Universitario de Alicante
Alicante, 03010
Hospital Universitario de La Princesa
Madrid, 28006
Hospital Universitario Miguel Servet
Zaragoza, 50009
Switzerland3 sites
University Hospital Zurich
Zurich, 8091
Universitätsspital Zürich
Zurich, CH-8091
Universtätsspital Zürich
Zurich, CH-8091
Canada1 site
Mount Sinai Services Inc. Dr George Charames
Toronto, Ontario, M5G 1X5
About this study
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
- Conditions
- Eosinophilic Esophagitis
- Being tested
- Etrasimod, Placebo
- Keywords
- Eosinophilic esophagitis, Esophageal eosinophilia, Etrasimod, APD334, EoE, Eosinophilic oesophagitis
- Medical subject headings
- Eosinophilic Esophagitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EtrasimodDrug
Also called APD334
Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
PlaceboDrug
Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
EtrasimodDrug
Also called APD334
Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
| Study group | Role | What they receive |
|---|---|---|
| Etrasimod Dose 1 | Experimental | Not described Receives: Drug: Etrasimod |
| Etrasimod Dose 2 | Experimental | Not described Receives: Drug: Etrasimod |
| Placebo and Etrasimod | Placebo comparator | Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period. Receives: Drug: Placebo; Drug: Etrasimod |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
Measured: Baseline, Week 16
Secondary outcomes (4)
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16
The DSQ was used to measure the frequency and intensity of dysphagia to solid food. DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score = (Sum of points from questions 2+3 in the daily DSQ)×14 days/(Number of diaries reported with non-missing data). DSQ scores can range from 0 to 84, with a higher score indicating worse dysphagia.
Measured: Baseline, Week 16
Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
Measured: Baseline, Week 16
Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Measured: Week 16
Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Measured: Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2020
- Study start15 Dec 2020
- Primary completion30 Sep 2022
- Study completion30 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Eosinophilic EsophagitisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Arena is a wholly owned subsidiary of Pfizer
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04682639
- Sponsor's protocol ID
- APD334-206
- Other IDs
- C5041009, 2020-003226-23
- Acronym
- VOYAGE
- Status last verified
- May 2024
- First submitted
- 19 Dec 2020
- Last updated
- 6 May 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, Nguyen-Cleary T, Su C, Yu J, Tan H, Cataldi F, Wu J, Wang W, Clax P, Woolcott JC, Hirano I. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):622-633. doi: 10.1016/S2468-1253(25)00062-7. Epub 2025 May 14.
PubMed 40381637Dubinsky MC, Wu J, McDonnell A, Lazin K, Goetsch M, Branquinho D, Modesto I, Armuzzi A. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. J Crohns Colitis. 2025 May 8;19(5):jjae173. doi: 10.1093/ecco-jcc/jjae173.
PubMed 39575597
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
- ClinicalTrials.gov ID
- NCT04682639
- Acronym / sponsor ID
- VOYAGE / APD334-206
- Conditions
- Eosinophilic Esophagitis
- Keywords
- Eosinophilic esophagitis, Esophageal eosinophilia, Etrasimod, APD334, EoE, Eosinophilic oesophagitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Collaborators
- Arena is a wholly owned subsidiary of Pfizer
- Study start
- 15 Dec 2020 (actual)
- Primary completion
- 30 Sep 2022 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 24 Dec 2020 (actual)
- Results
- Posted 26 Oct 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Etrasimod Dose 1 | Experimental | Drug: Etrasimod |
| Etrasimod Dose 2 | Experimental | Drug: Etrasimod |
| Placebo and Etrasimod | Placebo comparator | Drug: Placebo, Drug: EtrasimodParticipants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Have an eosinophilic esophagitis (EoE) diagnosis prior to screening and histologically active disease with an esophageal peak eosinophil count (PEC) of ≥ 15 eosinophils per high powered field (eos/hpf)
- Have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the Screening period
- Completion of the Week 24 study visit [including esophagogastroduodenoscopy (EGD)]
- Compliance with study procedures during the Double-Blind Treatment Period as assessed by the Investigator
- No notable safety concerns during the Double-Blind Treatment Period, as determined by the Investigator
Key exclusion criteria (11 listed)
- History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study
- Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD
- Use of corticosteroids for the treatment of EoE within 8 weeks prior to Screening EGD
- Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:
- Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EtrasimodAlso: APD334Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods. | Drug | Etrasimod Dose 1, Etrasimod Dose 2 |
| PlaceboParticipants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period. | Drug | Placebo and Etrasimod |
| EtrasimodAlso: APD334Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period. | Drug | Placebo and Etrasimod |
Primary outcome
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Time frame: Baseline, Week 16
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
4 secondary outcomes
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16
Time frame: Baseline, Week 16
Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Time frame: Baseline, Week 16
Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame: Week 16
Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame: Week 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40381637Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, Nguyen-Cleary T, Su C, Yu J, Tan H, Cataldi F, Wu J, Wang W, Clax P, Woolcott JC, Hirano I. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):622-633. doi: 10.1016/S2468-1253(25)00062-7. Epub 2025 May 14.
- Derived from this study: PubMed 39575597Dubinsky MC, Wu J, McDonnell A, Lazin K, Goetsch M, Branquinho D, Modesto I, Armuzzi A. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. J Crohns Colitis. 2025 May 8;19(5):jjae173. doi: 10.1093/ecco-jcc/jjae173.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Eosinophilic Esophagitis
Recruiting
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
Dysphagia, Eosinophilic Esophagitis
Active, not recruitingPhase 3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Eosinophilic Esophagitis
RecruitingObservational study
Natural History and Genetics of Food Allergy and Related Conditions
Food Allergy, Loeys-Dietz Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruiting
Patient-Centered Decision Support for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
256 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Etrasimod in people with Eosinophilic Esophagitis, run by Pfizer at 256 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 256 sites in United States, Australia, Belgium, Spain, Switzerland and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Oct 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 (time frame: Baseline, Week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04682639, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2024.